Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

Danaher Corporation
DHR - NYSE - $229.72 (as of ) ▼ -1.77%
-
Earnings Wed 27 Jan

Danaher opens the
books on Wednesday evening.

The median of 8 price targets is $2401, stock is $230, +4.5% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
B
Council 2/6 - Historical V1 score 51

B — FMP rating1.

Quick Answer

DHR Q4 consensus: revenue $7.5B1, EPS $2.521. Matt Gugino guided Biotechnology to 4-5% (previous 5.5%) in the Q3 earnings call2. 7 consecutive quarters of beat1.

$2.52 EPS Estimate Last year $2.23 - +13% YoY
5% Biotechnology Guidance Previous quarter was 5.5%
7 Beat Streak Expectations beaten consecutively for the last 7 quarters

Q3 FY26 EPS $2.11 vs $1.92 estimate: beat (+9.9%)1. Stock move on the next trading day: -1.8%1.

Next report

What to watch in Q4 FY26 (Jan 27, 2027)

  • EPS: consensus $2.52, against $2.23 in the same quarter a year ago (+13%).
  • Revenue: consensus $7.5B.

Watchlist

5 metrics stand out this quarter.

$8.57-$8.62 Expectation / Guide

Fy2026 Eps Guidance Raise

Danaher raised its FY2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60, reflecting Q3 outperformance.

Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026
4%-5% Investor Focus

2027 Core Growth Starting Point

2027_core_growth_starting_point

Management views 4%-5% core revenue growth excluding respiratory as the right starting point for 2027.

Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026
5.5% Risk Indicator

Q3 Core Growth Margin

Danaher's Q3 core revenue growth excluding respiratory accelerated to 5.5% with an adjusted operating margin of nearly 30%.

Julie Sawyer Montgomery, CEO - Q3 FY26 Earnings Call - October 21, 2026
4 Management Quote

Ceo Strategic Priorities

New CEO Julie Sawyer Montgomery set four strategic priorities: commercial excellence, innovation, talent, and effective capital allocation.

"As we enter this next chapter, we'll accelerate that ambition by focusing on 4 strategic priorities: commercial excellence, innovation, talent, and effective capital allocation."

- Julie Sawyer Montgomery, CEO - Q3 FY26 Earnings Call - October 21, 2026
mid-teens Investor Focus

Bioprocessing Orders

Bioprocessing orders grew mid-teens in Q3, with particular strength in upstream consumables and reagents.

Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +4.5%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 59
Klarman value - target upside +4.5%
Buffett quality - ROE score 3/5
Munger valuation - target upside +4.5%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
59.2 RSI 59.2 positive momentum, 50d above
MACD
+6.60 price above 50d - support positive
50d MA
$216 stock 6.6% above - short-term support
200d MA
$201 stock 14.2% above - long-term support
Volume (10d)
+29% increase - pre-earnings positioning
Resistance
$240
Analyst median target - upgrade trigger if broken
Current
$230
Pre-earnings position
Support
$171
Invalidation - close below this is a technical breakdown
Pattern
Range
$171-$240 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q4 FY25
$2.23 vs $2.16 est · Next-day price move: -2.2%
BEAT
Q1 FY26
$2.06 vs $1.94 est · Next-day price move: -5.4%
BEAT
Q2 FY26
$1.94 vs $1.85 est · Next-day price move: +0.1%
BEAT
Q3 FY26
$2.11 vs $1.92 est · Next-day price move: -1.8%

Three scenarios: what could happen?

Biotechnology below 35%

"In the fourth quarter, we expect core revenue growth excluding respiratory revenue to be in the 4%-5% range."

- Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026
Backlog concentration

No RPO/backlog concentration disclosed in Q3 earnings call.

Insider trading signal

Form 4 Q3 FY26: 4 transactions, net -$12.97M1.

Executive Action Amount Date
Blair Rainer director, President & CEO Sale -$2.46M 2026-08-24
Blair Rainer director, President & CEO Sale -$8.57M 2026-08-24
Blair Rainer director, President & CEO Sale -$1.70M 2026-08-24
SPOON ALAN G director Sale -$237.2K 2026-05-04

4 transactions · 4 sales / 0 purchases = net negative flow. Not large in absolute terms against a $161.5B market cap.

CapEx shock

Q3 CapEx $255.0M1. Q3 op margin 19.0%1 - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $2.52 + Biotechnology >= 5%
Threshold: EPS > $2.521 and Biotechnology >= 5%2.
Target: Break above median target $2401; high target $2751 upper bound.
Scenario B - In-Line
EPS approx $2.52 + Biotechnology 4-5%
Threshold: EPS approx $2.521, Biotechnology 4-5%, Q4 CapEx < $255.0M1.
Target: Consolidation in the band between current $2301 and median $2401.
Scenario C - Miss
EPS < $2.44 or Biotechnology < 35% or CapEx >= $255.0M
Threshold: EPS < $2.441 or Biotechnology < 35%2.
Current price $230 — above SMA200 $2011.

Market Outlook

What do analysts say? 8 price targets · 26 ratings

Wall Street Consensus
$240
12-month median target price (+4.5% gap to the analyst consensus median)
22
BUY
4
HOLD
0
SELL
Risk Management
$171
Invalidation level - critical support threshold
$216 - 50-day MA (above, +6.6%)
$201 - 200-day MA (above, +14.2%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - DHR Q4 FY26
B

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $2.521, Biotechnology guidance 4-5%2, CapEx threshold "below $255.0M". Three anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jan 27, 2027EARNINGSQ4 FY26 results (after market close) + earnings call
Jan 28, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Feb 23, 2027 – Mar 25, 2027FILING10-K due within 60–90 days of fiscal year end (by Feb 23, 2027 – Mar 25, 2027); the exact deadline depends on filer status
~Apr 29, 2027EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the DHR Q4 FY26 earnings preview cover?

This Danaher Corporation (DHR) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in DHR Q4 FY26 earnings?

Danaher Corporation (DHR): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Danaher Corporation (DHR): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

Danaher Corporation (DHR): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded